Phase II Study of SOL and Bevacizumab Combination Therapy in patients with Untreated Metastatic Colorectal Cancer.

Phase II Study of S-1, Oral Leucovorin, Oxaliplatin, and Bevacizumab Combination Therapy in patients with Untreated Metastatic Colorectal Cancer.

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220850

Enrollment

Registered

2009-09-08

Start date

2009-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Untreated metastatic colorectal cancer

Interventions

investigational material(s) Generic name etc : S-1(tegafur + gimeracil + oteracil potassium)/LV/L-OHP/Bevacizumab INN of investigational material : S-1:tegafur, gimeracil, oteracil potassium LV:folic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adequate oral intake At least one measurable lesion by RECIST criteria. ECOG Performance status:0-1

Exclusion criteria

Exclusion criteria: Serious drug hypersensitivity Prior history of peripheral neuropathy Diarrhea Simultaneously active double cancer

Design outcomes

Primary

Measure	Time frame
Response rate(RR) RECIST	—

Secondary

Measure	Time frame
Progression free survival(PFS) Time to progression(TTP) Time to treatment failure(TTF) Disease control rate(DCR) Overall survival(OS) Resection rate(Re-R) Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026